TrialPath
Recruiting

Vinpocetine in Patients With Parkinsonian Disease

NCT07229664 · Tanta University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian Disease
About this study
The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum
Eligibility criteria
Inclusion Criteria: Age ≥ 50 years Both male and female will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa Exclusion Criteria: Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Cardiovascular disease patients Patients with coagulation disorders Suffering from active malignancy Addiction to alcohol and / or drugs Known allergy to the studied medications
Study design
Enrollment target: 60 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2025-11-10
Estimated completion: 2027-11-20
Last updated: 2025-12-10
Interventions
Drug: Levodopa CarbidopaDrug: Vinpocetine
Primary outcomes
  • • Change in The Unified Parkinson's Disease Rating Scale (UPDRS). (6 months)
Sponsor
Tanta University · other
All locations (1)
Tanta UnuversityRecruiting
Tanta, Egypt